[Bilateral germ cell tumors of the testis].
Before the introduction of effective chemotherapy for testicular germ cell tumours, the relative frequency of bilateral germ cell tumours was about 1.6%. Now, as more patients with unilateral tumours survive, an increase in this percentage is to be expected. We therefore compared a series of 397 patients with testicular germ cell tumours observed between 1950-1975 with a series of 333 patients with such tumours observed between 1976-1985, after the introduction of chemotherapy with cis-platinum. In both series 7 patients had bilateral germ cell tumours, i.e. 1.8% of cases in the first series and 2.1% of cases in the second series. Since the second series of cases with a much shorter follow-up has an unbalanced ratio of seminomatous to non-seminomatous tumours, an increase in bilaterality can be expected. The prophylactic and therapeutic implications of an increase in bilateral germ cell tumours of the testis are discussed.
Wahl
C
C
Institut für Pathologie der Universität Zürich.
Hedinger
C
C
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D006801:Humans; D008297:Male; D009373:Neoplasms, Germ Cell and Embryonal / Q000628:therapy*; D009378:Neoplasms, Multiple Primary / Q000628:therapy*; D011379:Prognosis; D013736:Testicular Neoplasms / Q000628:therapy*
D002945:Cisplatin
Bilaterale Keimzelltumoren des Hodens.